Liege, Belgium, 29 September 2023 – 7:00 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the invitation to its special and extraordinary securities holders’ meetings that will be held on Monday, October 30th, 2023, at 2:00 PM (CEST).
The notice for the special and extraordinary general meetings, including a description of the formalities to participate in the meetings, is available on the website investors.mithra.com.
As referred in the meetings’ invitation published in the Belgian press, the right to participate in the special and extraordinary general shareholders’ meetings and to vote is subject to the prior registration of the shares under the relevant shareholder’s name on 16 October 2023 at midnight (CEST) (the “Record Date“), either by way of registration on the company’s share register, or either by way of registration in book entry form in an account held with a settlement institution or a certified account holder, without taking into account the number of shares held by the shareholder at the day of the special and extraordinary general meetings. Only persons who are shareholders on the Record Date are entitled to vote at the special and extraordinary general meetings.
The shareholders must indicate their willingness to participate in the special and extraordinary general meetings by the 24 October 2023 at the latest. This must be done by email to firstname.lastname@example.org, or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège.
Right to ask questions
The directors answer questions that are asked by the shareholders, in writing before the meetings, concerning the agenda, in accordance with legal provisions. These questions may be asked prior to the special and extraordinary general meetings by email to the address email@example.com or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège. These questions must be received by the Company on 24 October 2023 at the latest.
Further information relating to the abovementioned rights and the modalities for exercising them are available on the Company’s website (www.mithra.com).
Shareholders wishing to be represented at the meetings by a proxy holder must send the completed and signed1 proxy form to the Company on 24 October 2023 at the latest, by email, fax or mail to Mithra’s headquarter.
Further information on the exercise of this right is available on the Company’s website (www.mithra.com). The proxy and voting forms may be obtained on the Company’s website (www.mithra.com) or upon request at the Company’s registered office, or by email to firstname.lastname@example.org.
Shareholders wishing to be represented must comply with the registration and confirmation procedure described above.
All documents concerning the special and extraordinary general meetings that are required by law to be made available to shareholders as well as the text of the amended articles of association following the approval of the amendments proposed on the agenda may be consulted on the Company’s website (www.mithra.com) as from 29 September 2023. As from the same date, shareholders have the right to consult these documents on business days and during normal office hours, at the Company’s registered office and/or, upon display of their securities, obtain copies of these documents free of charge.
Requests for copies may also be made, free of charge, by mail (writing) marked for the attention Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège, or by email to email@example.com.
1 The form must be signed in writing or electronically, with a qualified electronic signature within the meaning of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended